Prognostic significance of interim <sup>18</sup>F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma

Yi-Wen SUN; Jin-Hua ZHAO; Wen-Li QIAO; Yan XING; Xiang CHEN; Jian-Hua SONG

doi:10.13538/j.1001-8042/nst.25.020304

Your Location：

Home >

Browse articles >

Prognostic significance of interim ¹⁸F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma

NUCLEAR CHEMISTRY, RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE | Updated：2021-01-20

- Prognostic significance of interim ¹⁸F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma
- Nuclear Science and Techniques Vol. 25, Issue 2, Article number: 020304(2014)
- Affiliations：
  
  1.Department of Nuclear Medicine, Shanghai First Poeple’s Hospital, Shanghai Jiaotong University, Shanghai200080, China
- Author bio：
  
  Corresponding author, zjh1963@gmail.com
- Funds：
- DOI：10.13538/j.1001-8042/nst.25.020304
  CLC：
Scan for full text
Yi-Wen SUN, Jin-Hua ZHAO, Wen-Li QIAO, et al. Prognostic significance of interim ¹⁸F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma. [J]. Nuclear Science and Techniques 25(2):020304(2014)
DOI：

Yi-Wen SUN, Jin-Hua ZHAO, Wen-Li QIAO, et al. Prognostic significance of interim ¹⁸F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma. [J]. Nuclear Science and Techniques 25(2):020304(2014) DOI： 10.13538/j.1001-8042/nst.25.020304.

摘要

Abstract

To detect the prognostic significance of interim ,18,F-FDG PET/CT SUV (standard uptake value) reduction (,Δ,SUV,max,) associated with Ki67 in patients with diffuse large B cell lymphoma (DLBCL). 47 DLBCL patients underwent PET/CT before initiation and after 2–4 cycles of chemotherapy were included. The SUV,max, of the dominant lesions were calculated. Ki67 positive indices were provided by enzyme-labeled immuno-histochemistry. SPSS17.0 was used for statistical analysis. ,Δ,SUV,max, of different groups were compared by t test. Receiver-operator characteristic analysis was performed to determine the optimal cutoff values. Kaplan-Meier analyses of PFS (Progression-free survival) were compared using log-rank test. The average of ,Δ,SUV,max, and ,Δ,SUV,max,% were 11.53 and 69.10%, respectively. The optimal cutoff values of ,Δ,SUV,max, and ,Δ,SUV,max,% were 11.45 and 82.92%, respectively. Higher ,Δ,SUV,max, and ,Δ,SUV,max,% indicated longer PFS (,p,<,0.001). The optimal cutoff value of Ki67 was 55%. Ki67,≥,55% was revealed to be an indicator of shorter PFS (,p,=0.019). Either ,Δ,SUV,max,≤,11.45 or Ki67,>,55% was defined as an indicator to poor outcome and scored 1 point. The PFS rate was 100% in patients scored 0 point, yet 0% in patients scored 2 points. PFS tended to be shorter along with the score getting higher (,p,=0.006). ,Δ,SUV,max, and Ki67 positive index were both of significance in DLBCL prognosis. The prognostic value may be confirmed when ,Δ,SUV,max, was accordant with Ki67.

关键词

Keywords

Diffuse large B cell lymphomaStandard uptake valueKi67Prognosis

references

Cheson B, Pfistner B, Juweid M, et al. J Clin Oncol, 2007, 25: 579-586.

Pregno P, Chiappella A, Bellò M, et al. Blood, 2012, 119: 2066-2073.

Cox M C, Ambrogi V, Lanni V et al. Leukemia Lymphoma, 2012, 53: 263-269.

Casasnovas R O, Meignan M, Berriolo-Riedinger A, et al. Blood, 2011, 118: 37-43.

Lin C, Itti E, Haioun C, et al. J Nucl Med, 2007, 48: 1626-1632.

Broyde A, Boycov O, Strenov Y, et al. Am J Hematol, 2009, 84: 338-343.

Bryant R J, Banks P M, O’Malley D P, et al. Histopathology, 2006, 48: 505-515.

Szczuraszek K, Mazur G, Jelen M, et al. Anticancer Res, 2008, 28: 1113-1118.

Kim S J, Kim B S, Choi C W, et al. Ann Oncol, 2007, 18: 1382-1387.

Terasawa T, Nihashi T, Hotta T, et al. J Nucl Med, 2008, 49: 13-21.

Wu X, Dastidar P, Pertovaara H, et al. Mol Imaging Biol, 2011, 13: 785-792.

Itti E, Lin C, Dupuis J, et al. J Nucl Med, 2009, 50: 527-533.

Itti E, Juweid M E, Haioun C, et al. J Nucl Med, 2010, 51: 1857-1862.

Nahmias C and Wahl L M. J Nucl Med, 2008, 49: 1804-1808.

Han B, Lin S, Yu L J, et al. Nucl Med Commun, 2009, 30: 831-837.

Ueda S, Tsuda H, Saeki T, et al. Breast Cancer, 2011, 18: 299-308.

Tang B, Malysz J, Douglas-Nikitin V, et al. Mol Imaging Biol, 2009, 11: 296-302.

Gaudio F, Giordano A, Perrone T, et al. Acta Haematol, 2011, 126: 44-51.

Shou Y, Lu J, Chen T, et al. J Cancer Res Ther, 2012, 8: 96-102.

Nguyen X C, Lee W W, Amin A M, et al. Nucl Med Mol Imaging, 2010, 44: 39-44.

Lanic H, Mareschal S, Mechken F, et al. Leukemia Lymphoma, 2012, 53: 34-42.

Herrmann K, Buck A K, Schuster T, et al. J Nucl Med, 2011, 52: 690-696.

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：Editorial Office of NST, 2019 Jialuo Road, Jiading, Shanghai 201800, China Postal code：201800
Email：nst@sinap.ac.cn
Technical support is provided by Beijing Founder electronics co., LTD 沪ICP备05005479号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Prognostic significance of interim 18F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma

DOI：10.13538/j.1001-8042/nst.25.020304

摘要

Abstract

关键词

Keywords

references

Prognostic significance of interim ¹⁸F-FDG PET/CT SUV reduction associated with Ki67 in patients with diffuse large B-cell lymphoma